Volume 17, Issue 1 p. 145-149
Brief Report

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia

Susan H. Fox MRCP, PhD,

Corresponding Author

Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom

Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool L9 7LJ, UKSearch for more papers by this author
Mark Kellett MRCP,

Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom

Search for more papers by this author
A. Peter Moore MRCP, MD,

Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom

Search for more papers by this author
Alan R. Crossman DSc,

Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom

Search for more papers by this author
Jonathan M. Brotchie PhD,

Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom

Search for more papers by this author
First published: 25 January 2002
Citations: 69

Abstract

Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double-blind, randomised, placebo-controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.